Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections

• Published in: Acta tropica Vol. 142; pp. 103 - 107
• Main Authors: Libraty, Daniel H., Zhang, Lei, Obcena, AnaMae, Brion, Job D., Capeding, Rosario Z.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2015
• Subjects: Adult; Antibodies, Anti-Idiotypic - immunology; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Dengue; Dengue - virology; Dengue virus; Dengue Virus - immunology; ELISA; Envelope protein; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G - immunology; Infant; Male; Predictive Value of Tests; Protein Structure, Tertiary; Serologic assay; Serologic Tests; Severity of Illness Index; Viral Envelope Proteins; Envelope protein; Serologic assay; Dengue; ELISA
• ISSN: 0001-706X; 1873-6254
• DOI: 10.1016/j.actatropica.2014.11.009

•The estimated rE dIII IgG levels to DENV2 and DENV3 correlated with the PRNT50.•Anti-DENVs 1–4 rE dIII IgG levels all correlated with each other.•rE dIII IgG levels to DENV2 and DENV3 inversely correlated with disease severity. Dengue is the most prevalent arthropod-borne viral illness in humans. The current gold standard serologic test for dengue virus (DENV) infection is a neutralizing antibody assay. We examined a DENV recombinant (r)E protein domain III IgG ELISA among infants with primary DENV infections. Infants experience a primary DENV infection in the presence of maternally derived anti-DENV IgG. The estimated DENV rE protein domain III IgG levels to the infecting serotype at the time of infant primary symptomatic DENV2 and DENV3 infections correlated with the 50% plaque reduction neutralization reciprocal antibody titers (PRNT50). Anti-DENVs 1–4 rE protein domain III IgG levels all correlated with each other, and the estimated rE protein domain III IgG level to the infecting serotype at the time of infection inversely correlated with dengue disease severity. The anti-DENV rE protein domain III IgG ELISA may be a useful and potentially high-throughput alternative to traditional DENV neutralizing antibody assays.